These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 28481631)

  • 1. Peak Inspiratory Flow Rate as a Criterion for Dry Powder Inhaler Use in Chronic Obstructive Pulmonary Disease.
    Mahler DA
    Ann Am Thorac Soc; 2017 Jul; 14(7):1103-1107. PubMed ID: 28481631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peak Inspiratory Flow as a Predictive Therapeutic Biomarker in COPD.
    Mahler DA; Halpin DMG
    Chest; 2021 Aug; 160(2):491-498. PubMed ID: 33812852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of inspiratory flow in selection and use of inhaled therapy for patients with chronic obstructive pulmonary disease.
    Mahler DA
    Respir Med; 2020 Jan; 161():105857. PubMed ID: 32056720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peak Inspiratory Flow Rate in Chronic Obstructive Pulmonary Disease: Implications for Dry Powder Inhalers.
    Ghosh S; Ohar JA; Drummond MB
    J Aerosol Med Pulm Drug Deliv; 2017 Dec; 30(6):381-387. PubMed ID: 28933581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and predictors of suboptimal peak inspiratory flow rate in COPD patients.
    Harb HS; Laz NI; Rabea H; Abdelrahim MEA
    Eur J Pharm Sci; 2020 Apr; 147():105298. PubMed ID: 32151707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of dry powder versus nebulized beta-agonist in patients with COPD who have suboptimal peak inspiratory flow rate.
    Mahler DA; Waterman LA; Ward J; Gifford AH
    J Aerosol Med Pulm Drug Deliv; 2014 Apr; 27(2):103-9. PubMed ID: 23745526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and factors associated with suboptimal peak inspiratory flow rates in COPD.
    Ghosh S; Pleasants RA; Ohar JA; Donohue JF; Drummond MB
    Int J Chron Obstruct Pulmon Dis; 2019; 14():585-595. PubMed ID: 30880948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA® Dry Powder Inhaler.
    Prime D; de Backer W; Hamilton M; Cahn A; Preece A; Kelleher D; Baines A; Moore A; Brealey N; Moynihan J
    J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):486-97. PubMed ID: 26372467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lung characteristics in elderly males and females patients with COPD: differences and optimal use of dry powder inhalers (DPIs).
    Terzano C; Oriolo F
    Eur Rev Med Pharmacol Sci; 2017 Jun; 21(11):2708-2716. PubMed ID: 28678314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FIDEPOC: Consensus on Inspiratory Flow and Lung Deposition as Key Decision Factors in COPD Inhaled Therapy.
    González-Torralba F; Baloira A; Abad A; Fuster A; García-Rivero JL; García-Sidro P; Márquez-Martín E; Palop M; Soler N; Velasco JL
    Int J Chron Obstruct Pulmon Dis; 2022; 17():1005-1015. PubMed ID: 35547784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and COPD phenotype for a suboptimal peak inspiratory flow rate against the simulated resistance of the Diskus® dry powder inhaler.
    Mahler DA; Waterman LA; Gifford AH
    J Aerosol Med Pulm Drug Deliv; 2013 Jun; 26(3):174-9. PubMed ID: 23025451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical relevance of dry powder inhaler performance for drug delivery.
    Demoly P; Hagedoorn P; de Boer AH; Frijlink HW
    Respir Med; 2014 Aug; 108(8):1195-203. PubMed ID: 24929253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lung Deposition and Inspiratory Flow Rate in Patients with Chronic Obstructive Pulmonary Disease Using Different Inhalation Devices: A Systematic Literature Review and Expert Opinion.
    Baloira A; Abad A; Fuster A; García Rivero JL; García-Sidro P; Márquez-Martín E; Palop M; Soler N; Velasco JL; González-Torralba F
    Int J Chron Obstruct Pulmon Dis; 2021; 16():1021-1033. PubMed ID: 33907390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Peak inspiratory flow generated through different analogue dry powder inhalers in Shenzhen healthy preschool children].
    Zhang QL; Zheng JP; Pan WH; He H; Chen GL; An JY; Yuan LF; Luo DF
    Zhonghua Er Ke Za Zhi; 2008 Feb; 46(2):98-103. PubMed ID: 19099680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inspiratory Flow Parameters Through Dry Powder Inhalers in Healthy Volunteers and Patients with Chronic Obstructive Pulmonary Disease (COPD): Device Resistance Does Not Limit Use in COPD.
    Jõgi R; Mattila L; Vahteristo M; Takala A; Lähelmä S; Vartiainen VA; Lindqvist A
    Int J Chron Obstruct Pulmon Dis; 2021; 16():1193-1201. PubMed ID: 33958863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suboptimal peak inspiratory flow rate in dry-powder inhaler users for chronic obstructive pulmonary disease in Korea.
    Moon JY; Kim SH; Kim Y; Lee H; Rhee CK; Ra SW; Lee CY; Park JH; Park YB; Yoo KH
    Pulm Pharmacol Ther; 2024 Jun; 85():102298. PubMed ID: 38604404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Vitro Dosing Performance of the ELLIPTA® Dry Powder Inhaler Using Asthma and COPD Patient Inhalation Profiles Replicated with the Electronic Lung (eLung™).
    Hamilton M; Leggett R; Pang C; Charles S; Gillett B; Prime D
    J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):498-506. PubMed ID: 26372465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determinants of Suboptimal Peak Inspiratory Flow Rates among Patients with Chronic Obstructive Pulmonary Disease in Southwest, Nigeria.
    Arawomo AO; Erhabor GE; Tanimowo MO; Awopeju OF; Adewole OO; Adeniyi BO; Afolabi BA; Ekundayo MW
    West Afr J Med; 2023 May; 40(5):553-561. PubMed ID: 37247343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing inhalation therapy in the aspect of peak inhalation flow rate in patients with chronic obstructive pulmonary disease or asthma.
    Hua JL; Ye XF; Du CL; Xie N; Zhang JQ; Li M; Zhang J
    BMC Pulm Med; 2021 Sep; 21(1):302. PubMed ID: 34560863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Measurement of inspiratory flow for the selection of the inhalation treatment device for asthma and COPD].
    Plavec D; Gluncić TJ; Gudelj I; Mise K
    Lijec Vjesn; 2012; 134(3-4):84-9. PubMed ID: 22768682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.